Effects of ODC1 downregulation on the proliferation, apoptosis, and sensitivity to platinum drugs of human SCLC cells H82 and H69

doi:10.3969/j.issn.1000-1565.2024.02.008

Abstract

Abstract: To explore the effect of the downregulation of ornithine decarboxylase1(ODC1)on the proliferation, apoptosis and platinum drugs sensitivity of human small cell lung cancer(SCLC)cells H82 and H69, the expression levels of ODC1 of the human SCLC cell lines were examined. H82 and H69 cells were infected with the LV-NC/ODC1-RNAi lentivirus, then the expression of ODC1 at the mRNA and protein levels was determined by real-time fluorescent quantitative PCR(q-PCR)and immunoblot assay(Western blot). CCK-8 assay, colony formation assay, flow cytometry and Western blot were used to detect- DOI:10.3969/j.issn.1000-1565.2024.02.008下调ODC1对人SCLC细胞H82、H69增殖、凋亡及铂类药物敏感性的影响高翔鹏^1,2,王晓芳¹,贺文艺^1,2,李玉苗¹,宋瑾¹,贾友超¹(1.河北大学附属医院肿瘤内科,河北省肿瘤放化疗机制与规程研究重点实验室,河北保定 071000;2.河北大学临床医学院,河北保定 071000)摘要:为探索下调鸟氨酸脱羧酶1(ornithine decarboxylase1, ODC1)对人小细胞肺癌(small cell lung cancer,SCLC)细胞H82、H69增殖、凋亡及铂类药物敏感性的影响,检测了人SCLC细胞系ODC1的表达水平,并利用LV-NC/ODC1-RNAi慢病毒感染H82、H69细胞后,通过实时荧光定量PCR(qPCR)和免疫印迹实验(West1ern blot)检测ODC1在mRNA和蛋白水平的表达.CCK-8法、软琼脂克隆形成实验、流式细胞术、Western blot等检测下调ODC1后细胞增殖、凋亡及对铂类药物敏感性的变化.结果显示,ODC1在人SCLC细胞系中多数高表达,且下调ODC1后人SCLC细胞H82、H69增殖减慢,凋亡明显增加,药物敏感性增强.说明下调ODC1抑制H82、H69细胞增殖,促进细胞凋亡,增强细胞对铂类药物的敏感性.关键词:鸟氨酸脱羧酶1(ODC1);小细胞肺癌(SCLC);增殖;凋亡;药物敏感性中图分类号:R73-3 文献标志码:A 文章编号:1000-1565(2024)02-0173-09Effects of ODC1 downregulation on the proliferation, apoptosis, and sensitivity to platinum drugs of human SCLC cells H82 and H69GAO Xiangpeng^1,2, WANG Xiaofang¹, HE Wenyi^1,2, LI Yumiao¹, SONG Jin¹, JIA Youchao¹(1. Hebei Key Laboratory of Cancer Radiotherapy and Chemotherapy, Department of Medical Oncology, Affiliated Hospital of Hebei University, Baoding 071000,China;2. School of Clinical Medicine, Hebei University, Baoding 071000, China)Abstract: To explore the effect of the downregulation of ornithine decarboxylase1(ODC1)on the proliferation, apoptosis and platinum drugs sensitivity of human small cell lung cancer(SCLC)cells H82 and H69, the expression levels of ODC1 of the human SCLC cell lines were examined. H82 and H69 cells were infected with the LV-NC/ODC1-RNAi lentivirus, then the expression of ODC1 at the mRNA and protein levels was determined by real-time fluorescent quantitative PCR(q-PCR)and immunoblot assay(Western blot). CCK-8 assay, colony formation assay, flow cytometry and Western blot were used to detect- 收稿日期:2022-11-16;修回日期:2023-04-21 基金项目:河北大学研究生创新项目(HBU2022ss002);2021年政府资助省级医学优秀人才项目——小细胞肺癌基础及转化创新团队第一作者:高翔鹏(1987—),男,河北大学硕士研究生,主要从事淋巴瘤、实体瘤的临床诊治及基础研究.E-mail:821408156@qq.com 通信作者:贾友超(1981—),男,满族,河北大学附属医院主任医师,主要从事淋巴瘤、实体瘤的临床诊治及基础研究.E-mail:youchaojia@163.com宋瑾(1982—),女,河北大学附属医院主管护师,主要从事肿瘤护理研究.E-mail:2705251562@qq.com第2期高翔鹏等:下调ODC1对人SCLC细胞H82、H69增殖、凋亡及铂类药物敏感性的影响 the changes of cell proliferation,apoptosis and sensitivity to platinum drugs after downregulation of ODC1. As a result, ODC1 was mostly highly expressed in human SCLC cell lines; the proliferation of human SCLC cells H82 and H69 slowed down; their apoptosis significantly increased and drugs sensitivity was enhanced. In summary, downregulation of ODC1 can inhibits the proliferation of human SCLC cells H82 and H69, promotes cell apoptosis, and enhances cell sensitivity to platinum drugs.

Key words: ornithine decarboxylase1(ODC1), small cell lung cancer(SCLC), proliferation, apoptosis, drugs sensitivity

CLC Number:

R73-3

GAO Xiangpeng, WANG Xiaofang, HE Wenyi, LI Yumiao, SONG Jin, JIA Youchao. Effects of ODC1 downregulation on the proliferation, apoptosis, and sensitivity to platinum drugs of human SCLC cells H82 and H69[J]. Journal of Hebei University(Natural Science Edition), 2024, 44(2): 173-181.

References

[1] SUNG H, FERLAY J, SIEGEL R L,et al.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA A Cancer J Clin, 2021, 71(3): 209-249. DOI:10.3322/caac.21660.
[2] 刘贤锡.多胺代谢与肿瘤治疗[J].山东大学学报(医学版),2011,49(10):67-72.
[3] MILLER-FLEMING L,OLIN-SANDOVAL V, CAMPBELL K,et al. Remaining mysteries of molecular biology: the role of polyamines in the cell[J]. J Mol Biol, 2015, 427(21): 3389-3406. DOI:10.1016/j.jmb.2015.06.020.
[4] KARLSSON A, HELOU K, WALENTINSSON A, et al. Amplification of Mycn, Ddx1, Rrm2, and Odc1 in rat uterine endometrial carcinomas[J]. Genes Chromosomes Cancer, 2001,31(4):345-356. DOI:10.1002/gcc.1153.
[5] NILSSON J A, KELLER U B, BAUDINO T A,et al. Targeting ornithine decarboxylase in Myc-induced lymphomagenesis prevents tumor formation[J]. Cancer Cell, 2005,7(5): 433-444. DOI:10.1016/j.ccr.2005.03.036.
[6] LAM SK, U KP, L YY,et al. Inhibition of ornithine decarboxylase 1 facilitates pegylated arginase treatment in lung adenocarcinoma xenograft models[J]. Oncol Rep,2018,40(4):1994-2004. DOI:10.3892/or.2018.6598.
[7] HOLBERT C E, CULLEN M T, CASERO R A,et al. Polyamines in cancer: integrating organismal metabolism and antitumour immunity[J]. Nat Rev Cancer, 2022, 22(8): 467-480. DOI:10.1038/s41568-022-00473-2.
[8] HOGARTY D, NORRIS, DAVIS,et al. ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma[J]. Cancer Res, 2008, 68(23): 9735-9745. DOI:10.1158/0008-5472.can-07-6866.
[9] EVAGELIOU N F, HABER M, VU A,et al. Polyamine antagonist therapies inhibit neuroblastoma initiation and progression[J]. Clin Cancer Res, 2016, 22(17):4391-4404. DOI: 10.1158/1078-0432.ccr-15-2539.
[10] KIM H I, SCHULTZ C R, BURAS A L,et al. Ornithine decarboxylase as a therapeutic target for endometrial cancer[J]. PLoS One,2017,12(12): e0189044. DOI:10.1371/journal.pone.0189044.
[11] SYMES A J,EILERTSEN M,MILLAR M,et al. Quantitative analysis of BTF3, HINT1, NDRG1 and ODC1 protein over-expression in human prostate cancer tissue[J]. PLoS One, 2013,8(12): e84295. DOI:10.1371/journal.pone.0084295.
[12] KAUL D, WU C L, ADKINS C B,et al.Assessing prostate cancer growth with mRNA of spermine metabolic enzymes[J]. Cancer Biol Ther, 2010,9(9):736-742. DOI:10.4161/cbt.9.9.11549.
[13] YE Z, ZENG Z, SHEN Y,et al. ODC1 promotes proliferation and mobility via the AKT/GSK3β/β-catenin pathway and modulation of acidotic microenvironment in human hepatocellular carcinoma[J]. Onco Targets Ther, 2019,12: 4081-4092. DOI:10.2147/ott.s198341.
[14] CHOI Y, OH S T, WON M A,et al. Targeting ODC1 inhibits tumor growth through reduction of lipid metabolism in human hepatocellular carcinoma[J]. Biochem Biophys Res Commun, 2016, 478(4): 1674-1681. DOI: 10.1016/j.bbrc.2016.09.002.
[15] SATO M,TOYAMA T, KIM M S,et al. Increased putrescine levels due to ODC1 overexpression prevents mitochondrial dysfunction-related apoptosis induced by methylmercury[J]. Life Sci, 2020, 256: 118031. DOI:10.1016/j.lfs.2020.118031.
[16] JIANG F, GAO Y, DONG C,et al. ODC1 inhibits the inflammatory response and ROS-induced apoptosis in macrophages[J]. Biochem Biophys Res Commun, 2018, 504(4): 734-741. DOI:10.1016/j.bbrc.2018.09.023.
[17] GECK R C, FOLEY J R, MURRAY STEWART T,et al. Inhibition of the polyamine synthesis enzyme ornithine decarboxylase sensitizes triple-negative breast cancer cells to cytotoxic chemotherapy[J]. J Biol Chem, 2020,295(19):6269-6277. DOI:10.1074/jbc.RA119.012376. (